| Selling sickness: the pharmaceutical industry and disease mongeringCommentary: Medicalisation of risk factors R Moynihan, P CG, I Heath, D Henry Bmj 324 (7342), 886-891, 2002 | 1626 | 2002 |
| Selling sickness: How the world's biggest pharmaceutical companies are turning us all into patients R Moynihan, A Cassels Greystone Books, 2008 | 1016 | 2008 |
| Preventing overdiagnosis: how to stop harming the healthy R Moynihan, J Doust, D Henry Bmj 344, e3502, 2012 | 818 | 2012 |
| Coverage by the news media of the benefits and risks of medications R Moynihan, L Bero, D Ross-Degnan, D Henry, K Lee, J Watkins, C Mah, ... New England journal of medicine 342 (22), 1645-1650, 2000 | 695 | 2000 |
| The making of a disease: female sexual dysfunction R Moynihan Bmj 326 (7379), 45-47, 2003 | 628 | 2003 |
| Impact of COVID-19 pandemic on utilisation of healthcare services: a systematic review R Moynihan, S Sanders, ZA Michaleff, AM Scott, J Clark, EJ To, M Jones, ... BMJ open 11 (3), e045343, 2021 | 611 | 2021 |
| The fight against disease mongering: generating knowledge for action R Moynihan, D Henry PLoS medicine 3 (4), e191, 2006 | 428 | 2006 |
| Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1: Entanglement R Moynihan Bmj 326 (7400), 1189-1192, 2003 | 407 | 2003 |
| Too much medicine?: Almost certainly R Moynihan, R Smith BMJ 324 (7342), 859-860, 2002 | 386* | 2002 |
| Key opinion leaders: independent experts or drug representatives in disguise? R Moynihan Bmj 336 (7658), 1402-1403, 2008 | 237 | 2008 |
| Expanding disease definitions in guidelines and expert panel ties to industry: a cross-sectional study of common conditions in the United States RN Moynihan, GPE Cooke, JA Doust, L Bero, S Hill, PP Glasziou PLoS medicine 10 (8), e1001500, 2013 | 208 | 2013 |
| Chronic kidney disease controversy: how expanding definitions are unnecessarily labelling many people as diseased R Moynihan, R Glassock, J Doust Bmj 347, 2013 | 208 | 2013 |
| Too much medicine; too little care P Glasziou, R Moynihan, T Richards, F Godlee Bmj 347, 2013 | 207 | 2013 |
| Who pays for the pizza? Redefining the relationships between doctors and drug companies. 2: Disentanglement R Moynihan Bmj 326 (7400), 1193-1196, 2003 | 175 | 2003 |
| Evidence-informed health policy 1–Synthesis of findings from a multi-method study of organizations that support the use of research evidence JN Lavis, AD Oxman, R Moynihan, EJ Paulsen Implementation Science 3, 1-7, 2008 | 161 | 2008 |
| Mapping the drivers of overdiagnosis to potential solutions T Pathirana, J Clark, R Moynihan Bmj 358, 2017 | 139 | 2017 |
| The marketing of a disease: female sexual dysfunction R Moynihan Bmj 330 (7484), 192-194, 2005 | 120 | 2005 |
| Using evidence to combat overdiagnosis and overtreatment: evaluating treatments, tests, and disease definitions in the time of too much R Moynihan, D Henry, KGM Moons PLoS medicine 11 (7), e1001655, 2014 | 115 | 2014 |
| Drugs for pre-osteoporosis: prevention or disease mongering? P Alonso-Coello, AL García-Franco, G Guyatt, R Moynihan BmJ 336 (7636), 126-129, 2008 | 113 | 2008 |
| Walking the tightrope: communicating overdiagnosis in modern healthcare KJ McCaffery, J Jansen, LD Scherer, H Thornton, J Hersch, SM Carter, ... Bmj 352, 2016 | 108 | 2016 |
David HenryHonorary, Bond University, UNSW and UMelbourne, Australia; ICES and UofT, Canada在 bond.edu.au 的电子邮件经过验证
David HenryHonorary, Bond University, UNSW and UMelbourne, Australia; ICES and UofT, Canada在 bond.edu.au 的电子邮件经过验证